BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 72,000 Shares of Company Stock

Posted by on Oct 6th, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 72,000 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the sale, the chief executive officer owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. This represents a 39.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

  • On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00.
  • On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
  • On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
  • On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total value of $2,664,630.00.
  • On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
  • On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
  • On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
  • On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
  • On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
  • On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.

BioNTech Stock Performance

NASDAQ:BNTX traded down $1.81 during midday trading on Tuesday, reaching $95.83. The stock had a trading volume of 882,705 shares, compared to its average volume of 1,088,476. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The stock has a market cap of $24.23 billion, a P/E ratio of -12.24 and a beta of 1.25. The firm has a fifty day simple moving average of $98.94 and a two-hundred day simple moving average of $95.06. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00.

BioNTech (NASDAQ:BNTX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the prior year, the company earned ($1.60) earnings per share. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. On average, equities analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC acquired a new stake in BioNTech in the 4th quarter valued at about $4,969,000. Bank of America Corp DE grew its position in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares during the last quarter. Amundi increased its stake in shares of BioNTech by 24.5% during the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after purchasing an additional 25,506 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of BioNTech during the 2nd quarter worth approximately $2,520,000. Finally, Flossbach Von Storch SE acquired a new position in shares of BioNTech during the 2nd quarter worth approximately $207,142,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on BNTX shares. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. Citigroup decreased their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a report on Wednesday, September 16th. Canaccord Genuity Group reduced their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, UBS Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Get Our Latest Research Report on BNTX

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

Featured Stories

Insider Buying and Selling by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.